Evommune (EVMN) Cash & Equivalents (2024 - 2026)

Evommune (EVMN) has reported Cash & Equivalents for 3 consecutive years, with $48.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 747.09% year-over-year to $48.3 million; the TTM figure through Mar 2026 stood at $48.3 million (up 747.09% YoY), while the FY2025 annual figure was $44.1 million, up 171.07% from the prior year.
• Cash & Equivalents climbed to $48.3 million in Q1 2026 per EVMN's latest filing, from $44.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $48.3 million in Q1 2026 and bottomed at $5.7 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $26.6 million across 3 years, with a median of $22.5 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Equivalents jumped 47.79% — and 2026, when it soared 747.09%.
• Evommune's Cash & Equivalents stood at $16.3 million in 2024, then soared by 171.07% to $44.1 million in 2025, then climbed by 9.66% to $48.3 million in 2026.
• Business Quant data shows EVMN's Cash & Equivalents at $48.3 million in Q1 2026, $44.1 million in Q4 2025, and $26.8 million in Q3 2025.